What the FDA labels say about taking them together
Lisinopril and temsirolimus
Lisinopril's FDA label of January 2, 2025 names temsirolimus in its drug interactions section; temsirolimus's label does not name lisinopril itself but warns about its class (ACE inhibitors). The lisinopril label: “7.7 mTOR Inhibitors Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema.”
Check it at the source: the lisinopril FDA label on DailyMed (effective January 2, 2025, Upsher-Smith Laboratories, LLC); the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the lisinopril label say about temsirolimus?
Lisinopril label, drug interactions7.7 mTOR Inhibitor s Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema. [ see Warnings and Precautions (5.2) ]
Lisinopril label, warnings and precautionsPatients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema. [see Drug Interactions (7.7 , 7.8)].
Source: FDA drug label (Qbrelis, NDA208401), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set 9f6e4e57-a489-4b36-b093-b93865d3717c), via openFDA
Source: FDA drug label (Zestril), NDA019777 (Twi Pharms), as published by Upsher-Smith Laboratories, LLC, effective January 2, 2025 (SPL set 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8), via openFDA; the full label on DailyMed
What does the temsirolimus label say about lisinopril?
Temsirolimus's label does not name lisinopril itself; it warns about its class (ACE inhibitors):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lisinopril | Temsirolimus | |
|---|---|---|
| Labeled for | High blood pressure, Heart attack and coronary artery disease, Heart failure | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0254 per tablet 20 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once